← All trials

NCT05312294

Phase 3Interventional

Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

View on ClinicalTrials.gov ↗

Timeline

Start date
Dec 7, 2020
Primary completion
Sep 3, 2021
Completion date
Nov 15, 2021
First posted
Apr 5, 2022
Last posted
Apr 5, 2022
Enrollment
654
Arms / groups
2 / —
Source
AACT · ctgov ingestion

Sponsors

Drugs studied

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.